Opinion
Video
Inflation Reduction Act: Impact on Health Care Systems’ Utilization of BTK Inhibitors
Panelists discuss how the Inflation Reduction Act (IRA) might influence health care systems’ selection and utilization of Bruton tyrosine kinase (BTK) inhibitors, particularly through changes in pricing, reimbursement policies, and treatment access.
Video content above is prompted by the following:
The Inflation Reduction Act is poised to significantly influence how health systems approach the selection and use of BTK inhibitors in the treatment of chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL). By introducing price negotiations and capping out-of-pocket costs—particularly for drugs like ibrutinib—it creates a pathway for broader access to highly effective, targeted therapies. Health systems may begin to prioritize these more affordable agents over older, more toxic chemotherapy regimens, especially in lower-resource settings or when treating patients on fixed incomes. This change could drive increased adoption of modern therapies that improve outcomes while reducing overall toxicity and the need for supportive care.
Despite the potential for cost-related gains, there are complexities. For example, one BTK inhibitor has had its indication for MCL withdrawn after post-approval studies failed to demonstrate a survival benefit and revealed increased toxicity. This limits its labeled use, although off-label prescribing remains a viable option, especially when evidence supports efficacy and the affordability is unmatched. With cost caps in place, even off-label use might become more attractive for patients who previously could not access these therapies due to financial constraints. This could help ensure that treatment decisions are made based more on clinical need and less on economic limitations.
The broader impact may be felt in efforts to reduce disparities in cancer care. Historically, underrepresented populations have had delayed access to novel treatments, often due to systemic barriers and cost. By making advanced therapies more affordable and broadly accessible, the new policy may help improve health equity. Reducing the financial burden of care can also lead to greater treatment adherence, fewer hospitalizations, and better quality of life. In the long run, such reforms could shift the healthcare system toward a more sustainable, equitable model that supports both clinical effectiveness and affordability.
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
